Valuation — not yet established
No valuation for NeuroGen Pharma is on record yet — no priced round, mark, or trade has surfaced in our sources. Total raised ($680.0M) and the funding record below are the closest available signals.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
See the evidence behind this price
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for NeuroGen Pharma
Create free account
No card required
Funding history
1 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Nov 2024 | Buyout/LBO | $680.0M | ▮ | ▮ |
How NeuroGen Pharma's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For NeuroGen Pharma, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →
Frequently asked
- How much has NeuroGen Pharma raised?
- NeuroGen Pharma has raised $680.0M in total funding across 1 recorded rounds.
- When did NeuroGen Pharma last raise?
- NeuroGen Pharma last raised in Nov 2024 (Buyout/LBO), raising $680.0M.